



ThermaLIFE deal

NEWLY released pain relief cream Thermalife (**PD Tue**) is set for some major exposure to aching ageing joints and muscles, after being accepted as a sponsor of the upcoming XIII Australian Masters Games in South Australia.

Publicly listed parent company Pharmanet Group said the move would see awareness of the OTC pharmacy product raised among "thousands of participants and supporters from all over Australia".

Fake tanning alert

THE UK Medicines and Healthcare products Regulatory Agency has issued a warning about a new "tanning nasal spray" called Ubertan.

The product, which is reportedly being offered illegally in gyms and beauty salons, is not a licensed medicine meaning there is "no evidence of safety, quality or that it works," the MHRA said.

UTS launches Pharmacy School

THE University of Technology Sydney has today announced the debut of a new school of pharmacy.

From 2012 UTS will offer a graduate-entry masters degree as well as PhDs, promising to deliver graduates who are eligible for registration as a pharmacist "and can manage the new and increasingly complex business, service delivery and health dimensions of the profession".

The school is headed up by UTS Professor of Pharmacy Practice, Charlie Benrimoj, who moved across from Sydney University earlier this year.

"The UTS pharmacy school will become only the second of such schools here in Sydney with its population of four million," said UTS Vice-Chancellor Professor Ross Milbourne.

"We believe the courses will be in demand from graduates seeking to enhance their careers in this growing city," he said.

The pharmacy school is the first fruits of a fledgling strategy at UTS to boost its health offerings.

Benrimoj said the development of the program meant UTS had been in a unique position to employ best practice at every stage.

"Working with key professional

UK riot advice

THE Royal Pharmaceutical Society of Great Britain has advised British pharmacists to take "all appropriate actions to reduce the impact of the riots on patients," after several days of unrest in London and several other UK cities.

partners and an educational designer, our pharmacy academics have created an innovative and rigorous graduate entry curriculum.

"The programs utilise cutting-edge tools to integrate pharmaceutical science with clinical practice, technology and interdisciplinary skills," he said.

Preliminary Australian Pharmacy Council Accreditation has already been received for the new masters program, and a website promoting the course went live this morning at www.pharmacy.uts.edu.au.

The course is open to graduates who have a science or related degree, and enables entry into the internship program leading to registration as a pharmacist.

"It has been designed to address the increasing need to produce graduates who can fulfil the expanded and diverse roles in pharmacy that primarily focus on the quality use of medicine and service provision," Benrimoj said.

A series of information evenings about the new course will be held in September and October.

ASMI 2011 awards

THE Australian Self-Medication Industry is calling for nominations in its upcoming Sales & Marketing Awards, which will be announced at its Sydney conference in Nov.

This year the awards program has been significantly reviewed, with an overhaul of the entry and judging criteria to "align more closely to a business mindset".

The judging panel will be expanded from four to six, to ensure that each category has four "non-conflicted" judges, and the 'Best Marketing Campaign' category has been split into two - above and below \$500,000 - to allow more opportunities for smaller campaigns to be recognised.

There's also a new focus on health literacy to identify how campaigns have helped consumers better understand their health.

Entry is only open to ASMI members, with submissions due by close of business on 09 September.

Categories include Best PR Initiative, Best Self Care Program, Best Marketing Campaign, Best Sales Force Initiative and Best Launch of a Healthcare Product.



**PBS-APPROVAL
NUMBER
FOR SALE**

Available for long
distance relocation

Contact: Peter Marshall

0417 721 203

peterm@pharmacysolutions.com.au

**WE WILL PAY YOU
TO BE A CHEMSAVE COMPLIANT MEMBER**

Yes, we pay you! And because we're happy to pay, we offer a number of easy ways to be a Chemsave compliant member!

Plus, as a Chemsave compliant member, we will provide you with a suite of profit-boosting member benefits for **FREE!**



Full Branding Option with FREE Signage!

With a choice of membership levels to suit all pharmacies, all the way up to full branding, now is the time to join Chemsave!

**CLICK
HERE**

TO FIND OUT HOW MUCH WE
WILL PAY YOU TO BE A CHEMSAVE
COMPLIANT MEMBER



WIN A GAIA BODYCARE PACK



Pharmacy Daily has teamed up with **GAIA** this week and is giving away Bodycare packs to five lucky readers.

Each pack is valued at \$59.80 and contains two body washes and two body moisturisers.

GAIA Bodycare soap-free washes and skin-softening moisturisers contain natural and organic ingredients for naturally soft, beautifully healthy skin every day.



Australian made and owned, GAIA Bodycare has been specially formulated for the skincare needs of women and comes to us from the makers of GAIA Natural Baby. Contact National Pharmacy Manager Rebecca for opening order deals and special offers - m:0418 293 366 or rebecca@rebles.com.au



For your chance to win this fantastic GAIA Bodycare pack, go to the website: www.gaiaskinnaturals.com, then email your answer to the question below by COB on Friday to: comp@pharmacydaily.com.au

In 25 words or less tell us why you stock GAIA Bodycare products – or why you should!

Five most creative entries will win this great prize and their names will be announced in **Pharmacy Daily** on Monday 15th Aug.

Travel Specials

WELCOME to *Pharmacy Daily's* travel feature. Each week we highlight a couple of great travel deals for the pharmacy industry.

LAKE Crackenback Resort is offering a Stay 4, Pay 3 deal during the month of August, now priced from \$723 per person.

The deal applies to Monday arrivals only and is for a two bedroom gold mountain view chalet with four people sharing.

The package includes accom, breakfasts and a three day Perisher lift ticket.

See lakecrackenback.com.au.

CRUISE WEEKLY

Sponsored by Cruise Weekly your FREE cruise newsletter
Subscribe now

www.cruiseweekly.com.au

TGA set for labelling review

THE Therapeutic Goods Administration has announced a review of the labelling and packaging regulatory framework covering prescription, OTC and complementary medicines.

A consultation paper is set to be released in October, with the move following the recent review to improve the transparency of the TGA which contained a number of recommendations about labelling.

Submissions to the review included a number of comments about the TGA's role in regulating and monitoring medicine labelling, including "notable concerns about the placement of pharmacy labels over manufacturers' labels, thereby covering mandatory information including important dosage and active ingredient information".

Other issues raised included calls for a consistent approach by the TGA to the approval of product names "to ensure certainty for industry and safety for consumers".

It's also been suggested that details of non-active ingredients also be included on therapeutic goods labels to help users make "informed decisions".

Buy some tissues

THE organisers of the Blue September cancer campaign are urging independent pharmacies across Australia to buy a carton of specially produced pharmacy-only Quilton toilet tissues.

Each carton contains 10 packs, and \$2 from every pack sold will be donated to Blue September, with the campaign so far raising over \$80,000 and strong support from major banner groups.

Symbion, Sigma and API are all part of the promotion, and there's also a competition for the most creative Blue September window or gondola end display, with a major prize of a trip to California.

For more information contact wholesalers or see guild.org.au.

DISPENSARY CORNER

MYLANTA or possibly a Prep-Kit needed urgently.

A Chicago-based home handyman has been charged with "felony theft" after allegedly stealing a diamond ring which was in the bathroom of a house he was working on.

Accused of the theft, 30-year-old Wilfredo Gonzalez at first denied taking the jewellery but after a brief confrontation attempted to hide the evidence by taking the ring out of its hiding place and swallowing it.

Police were called and took the tradesman to hospital where an X-ray revealed the sparkler making its way through his gastrointestinal canal.

Reports state that officers "subsequently retrieved the missing ring," but didn't specify how this was done.

August MIMS Monthly Medicine Update

NEW PRODUCTS

Brilinta (ticagrelor) is a selective and reversible adenosine diphosphate (ADP) receptor antagonist acting on the platelet P2Y₁₂ ADP-receptor to prevent ADP-mediated platelet activation and aggregation. Brilinta, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI)) including patients managed medically, and those managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG). It is contraindicated in active pathological bleeding, history of intracranial haemorrhage, moderate to severe hepatic impairment. Coadministration of ticagrelor with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir) is also contraindicated, as it may lead

to a substantial increase in exposure to ticagrelor. Brilinta treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily. Treatment is recommended for at least 12 months. Brilinta is available as a 90mg tablet in a calendar pack of 14's (sample) and 56's.

NEW INDICATIONS

Anzemet (dolasetron mesylate) IV injection is now indicated for use in adults for the prevention and treatment of postoperative nausea and vomiting. Anzemet oral tablet is indicated for use in adults for the prevention of postoperative nausea and vomiting.

Pegasys (peginterferon alfa-2a) is now indicated as monotherapy for the treatment of chronic hepatitis C in treatment naïve patients.

Pegasys RBV combination therapy (peginterferon alfa-2a + copegus) is now indicated for the treatment of chronic hepatitis C in patients with clinically stable

human immunodeficiency virus (HIV) who have previously not received interferon therapy.

Sprycel (dasatinib) is now indicated for the treatment of adults aged 18 years or over with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase.

SAFETY RELATED CHANGES

Gingivitis, anaphylactic reaction, oedema (tongue, lip, pharyngeal), weight decrease, slurred speech have been noted with **Actiq (fentanyl citrate)**.

Adrenaline injection (adrenaline hydrochloride) should be used with caution in patients suffering from autonomic dysreflexia (hyperreflexia), particularly in spinal cord injury (e.g. tetraplegics).

Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving tricyclic antidepressants, e.g. **Anafranil (clomipramine)**.

Anzemet (dolasetron mesylate) is now contraindicated in adult patients using dolasetron administered intravenously for the prevention of nausea and vomiting associated with initial and repeat courses of cancer chemotherapy.

Avandamet (rosiglitazone + metformin hydrochloride) trials suggest that the rosiglitazone risk of bone fracture may also apply to men, although the risk of fracture among women appears higher than that among men.

There have been reports of myocardial infarction and cerebrovascular accident including ischaemic and haemorrhagic events in patients taking **Champix (varenicline tartrate)**. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out.

Cymbalta (duloxetine hydrochloride), may increase the risk of bleeding events, including gastrointestinal bleeding. Therefore,

caution is advised in patients taking duloxetine concomitantly with anticoagulants and/or medicinal products known to affect platelet function (e.g. NSAIDs, aspirin) and in patients with known bleeding tendencies.

There have been very rare reports of peripheral demyelinating polyneuropathies (including Guillain-Barré syndrome) associated with **Enbrel (etanercept)**.

Olmemet (olmesartan medoxomil) is now contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min) and in patients with severe hepatic impairment (Child-Pugh score 10-15) or biliary obstruction.

Progynova (oestradiol valerate) is now contraindicated in patients with a high risk of venous or arterial thrombosis.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing always refer to the full Product Information.